Change in practice after the surfactant, positive pressure and oxygenation randomised trial

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 99, Issue 5, 2014, Pages

  LeVan, Jaclyn M ^a,b   Brion, Luc P ^a   Wrage, Lisa A ^c   Gantz, Marie G ^c   Wyckoff, Myra H ^a   Sánchez, Pablo J ^a,d   Heyne, Roy ^a   Jaleel, Mambarambath ^a   Finer, Neil N ^e   Carlo, Waldemar A ^f   Das, Abhik ^c   Stoll, Barbara J ^g   Higgins, Rosemary D ^h  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Pediatrix Medical Group   (United States)

^c RTI INTERNATIONAL   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; DEXAMETHASONE; INDOMETACIN; SURFACTANT; LUNG SURFACTANT;

ARTICLE; COHORT ANALYSIS; COMFORT; CONGENITAL MALFORMATION; CONTROLLED STUDY; ENDOTRACHEAL INTUBATION; FEASIBILITY STUDY; FEMALE; GESTATIONAL AGE; HEALTH CENTER; HUMAN; INFANCY; INFANT; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MULTICENTER STUDY; NEWBORN; NEWBORN PERIOD; OUTCOME VARIABLE; OXYGEN SATURATION; OXYGENATION; POSITIVE END EXPIRATORY PRESSURE; PREMATURITY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETROLENTAL FIBROPLASIA; RISK FACTOR; BRONCHOPULMONARY DYSPLASIA; CLINICAL TRIAL; DELIVERY ROOM; FACTUAL DATABASE; INFANT, PREMATURE, DISEASES; MASS COMMUNICATION; METHODOLOGY; NEWBORN INTENSIVE CARE; OXYGEN THERAPY; PROCEDURES; PROFESSIONAL PRACTICE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; UNITED STATES; UTILIZATION;

BRONCHOPULMONARY DYSPLASIA; CONTINUOUS POSITIVE AIRWAY PRESSURE; DATABASES, FACTUAL; DELIVERY ROOMS; DIFFUSION OF INNOVATION; FEASIBILITY STUDIES; FEMALE; HUMANS; INFANT, EXTREMELY PREMATURE; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; INTENSIVE CARE, NEONATAL; INTUBATION, INTRATRACHEAL; MALE; OXYGEN INHALATION THERAPY; PROFESSIONAL PRACTICE; PULMONARY SURFACTANTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84906791451     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/archdischild-2014-306057     Document Type: Article

References (16)

1. Finer N, Carlo A, Walsh MC, et al. SUPPORT study group of the Eunice Kennedy Shriver NICHD Neonatal Research Network. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med 2010;362:1970-79.
2. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Carlo WA, Finer NN, et al. Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med 2010;362:1959-69.
3. Finer NN, Carlo WA, Duara S, et al. National Institute of Child Health and Human Development Neonatal Research Network. Delivery room continuous positive airway pressure/positive end-expiratory pressure in extremely low birth weight infants: a feasibility trial. Pediatrics 2004;114:651-7. (Pubitemid 41529520)
4. LeVan JM, Wyckoff MH, Jaleel MA, et al. Change in care among nonenrolled patients during and after a randomized trial. Pediatrics 2013;132:e960-70.
5. Tyson JE, Parikh NA, Langer J, et al. Intensive care for extreme prematurity - moving beyond gestational age. N Engl J Med 2008;358:1672-81. (Pubitemid 351549914)
6. Ambalavanan N, Van Meurs KP, Perritt R, et al. Predictors of death or bronchopulmonary dysplasia in preterm infants with respiratory failure. J Perinatol 2008;28:420 -6.
7. Schmidt B, Roberts RS, Fanaroff A, et al. Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP). J Pediatr 2006;148:730-4.
8. Schmidt B, Roberts RS, Davis P, et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med 2007;357:1893-902. (Pubitemid 350074685)
9. Tyson JE, Wright LL, Oh W, et al. Vitamin A supplementation for extremely-low-birth-weight infants. N Engl J Med 1999;340:1962-8. (Pubitemid 29288272)
10. Fanaroff AA, Korones SB, Wright LL, et al. Incidence, presenting features, risk factors and significance of late onset septicemia in very low birth weight infants. The National Institute of Child Health and Human Development Neonatal Research Network. Pediatr Infect Dis J 1998;17:593-8. (Pubitemid 28340869)
11. Clyman R, Cassady G, Kirklin JK, et al. The role of patent ductus arteriosus ligation in bronchopulmonary dysplasia: reexamining a randomized controlled trial. J Pediatr 2009;154:873-6.
12. Mestan KK, Steinhorn RH. Fetal origins of neonatal lung disease: understanding the pathogenesis of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2011;301:L858-9.
13. Bose C, Van Marter LJ, Laughon M, et al. Fetal growth restriction and chronic lung disease among infants born before the 28th week of gestation. Pediatrics 2009;124:e450-8.
14. Sharma P, McKay K, Rosenkrantz TS, et al. Comparisons of mortality and pre-discharge respiratory outcomes in small-for-gestational-age and appropriate-for-gestational-age premature infants. BMC Pediatr 2004;4:9.
15. Shankaran S, Fanaroff AA, Wright LL, et al. Risk factors for early death among extremely low-birth-weight infants. Am J Obstet Gynecol 2002;186:796-802. (Pubitemid 34494366)
16. Narendran V, Donovan EF, Hoath SB, et al. Early bubble CPAP and outcomes in ELBW preterm infants. J Perinatol 2003;23:195-9. (Pubitemid 36656518)